Rekvina Laboratories Share Price Today

Rekvina Labs subsidiary Radiant Parenterals shuts plant for vial line upgrade

Radiant Parenterals Limited, a wholly owned subsidiary of Rekvina Laboratories, will halt manufacturing from October 28, 2026. The shutdown is scheduled for renovation, upgradation, and installation of an additional vial manufacturing line. Rekvina Laboratories will provide updates to stock exchanges upon resumption of operations. The move is disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rekvina Labs AGM voting results: all 4 resolutions pass unanimously

All 4 resolutions at Rekvina Laboratories' 38th AGM on September 29, 2026 passed with 100% votes in favour and zero votes against. Total valid votes polled stood at 4,652,440, representing 41.85% of total outstanding shares of 11,115,750. Promoter and promoter group polled 3,029,353 votes (35.39% of their holding); public non-institutions polled 1,623,087 votes (63.48% of their holding). Resolutions included adoption of FY26 audited financial statements, re-appointment of Mrs. Ilaben Pathak, and appointment of Mr. Prateek Jain and Mr. Jay Chintan Patel as independent directors. E-voting was facilitated through CDSL; scrutinizer's report submitted by M/s. S Bhattbhatt & Co., Practising Company Secretaries, Vadodara.

Rekvina Labs MD Amit Shah resigns; registered office shifts to Vadodara

Rekvina Laboratories Limited announced the resignation of Managing Director Amit Shah effective September 11, 2026. The resignation was attributed to personal reasons and personal commitments by the director. The Board also approved a change in the registered office address within Vadodara effective September 23, 2026. Amit Shah held no directorships in other listed entities as per the disclosure.

Rekvina Laboratories accepts resignation of MD Amit Mukesh Shah

Rekvina Laboratories accepts resignation of Amit Mukesh Shah as MD and Director. Effective date of resignation is September 11, 2026. Cited reason is personal commitments and personal reasons. Filing made to BSE under Regulation 30 of SEBI Listing Regulations.

Rekvina Laboratories FY26 Results: Net loss widens 86% to ₹25.47 lakh

Net loss widened to ₹25.47 lakh in FY26 from ₹13.71 lakh in FY25. Revenue from operations began at ₹126.54 lakh after nil in prior year. Borrowings rose sharply to ₹147.27 lakh, mostly from related parties. Board approved AGM notice and new independent director appointments.

Rekvina Labs accepts resignation of Company Secretary Deepak Khandelwal

Rekvina Laboratories accepted the resignation of its Company Secretary and Compliance Officer. Deepak Khandelwal stepped down effective September 2, 2026, citing personal reasons. The disclosure was made in compliance with Regulation 30 of SEBI LODR Regulations. The company is processing outstanding dues and service certificates for the outgoing officer.